IDH1 and central nervous system cancer: Numerous studies have also demonstrated that IDH mutations play an important role in diagnosing, evaluating medication effectiveness, predicting survival, and reducing the invasiveness of biomarkers associated with glioma, and are widely deemed the most significant genetic alteration (13–16).